Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
The Oncologist · 02.06.2023 · 28 (6) · e379-e390
DOI: 10.1093/oncolo/oyad001 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Oncologist, online erschienen am 23.02.2023. Verfasst von Bruce C Tiu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Antineoplastic Agents, Acute Kidney Injury. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Clinical trials of immune checkpoint inhibitors (ICIs) often do not include patients with advanced chronic kidney disease (CKD). We aimed to determine the safety of ICIs in patients with cancer and advanced CKD (stages 4-5 CKD, estimated glomerular filtration rate [eGFR] <30 mL/minute/1.73 m2). Patients and Methods Patients with advanced CKD from the Mass General Brigham network who received ICIs (n = 91) were compared against those receiving nephrotoxic (n = 113) and non-nephrotoxic (n = 130) antineoplastic therapies, respectively. Rates of new-onset kidney failure (end-stage kidney disease or sustained eGFR ≤10 mL/minute/1.73 m2) and AKI were compared. Among ICI-treated patients, we modeled Fine-Gray subdistribution hazards to compare immune-related adverse event (irAE) risk and used Kaplan-Meier analysis to compare overall survival in patients with advanced CKD to those with eGFR ≥30 mL/minute/1.73 m2.
Results
Rates of new-onset kidney failure were similar at 1 year following initiation of ICIs (10.0%), nephrotoxic (6.2%), and non-nephrotoxic antineoplastic therapies (9.3%) (P = .28). AKI rates were also similar: 17.5%, 17.6%, and 20% of patients in each cohort, respectively (P = .87). Advanced CKD did not increase the risk of developing irAEs (adjusted hazard ratio [HR] 1.28, 95% CI, 0.91-1.81). However, patients with advanced CKD who received ICIs had a decreased overall survival compared with patients with eGFR ≥30 mL/minute/1.73 m2 (HR 1.30 for death, 95% CI, 1.02-1.66, P = .03).
Conclusion
ICIs are not associated with increased risk of AKI or new-onset kidney failure compared with other antineoplastic therapies in patients with advanced CKD. Advanced CKD did not increase the risk of extra-renal irAEs, although these patients suffered from lower overall survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Harvard Medical School, Boston, MA, USA.
- Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.
- Department of Medicine, Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
ORCID-Profile: Bruce C Tiu, Ian A Strohbehn, David E Leaf, Meghan E Sise
Zitieren
APA
Tiu, B. C., Strohbehn, I. A., Zhao, S., Ouyang, T., Hanna, P., Wang, Q., Gupta, S., Leaf, D. E., Reynolds, K. L., & Sise, M. E. (2023). Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. The Oncologist, 28(6), e379-e390. https://doi.org/10.1093/oncolo/oyad001
Vancouver
Tiu BC, Strohbehn IA, Zhao S, Ouyang T, Hanna P, Wang Q, et al. Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. The Oncologist. 2023;28(6):e379-e390. doi:10.1093/oncolo/oyad001
BibTeX
@article{Tiu2023,
author = {Tiu, Bruce C and Strohbehn, Ian A and Zhao, Sophia and Ouyang, Tianqi and Hanna, Paul and Wang, Qiyu and Gupta, Shruti and Leaf, David E and Reynolds, Kerry L and Sise, Meghan E},
title = {Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {6},
pages = {e379--e390},
doi = {10.1093/oncolo/oyad001}
}
EUVIMED